VivoSeq
Infectious Disease

Typhoid Fever

17

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Typhoid Fever is an emerging landscape with 17 programs across 8 companies. The most active players are GSK, Avant Immunotherapeutics, Emergent BioSolutions. 9 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

7 programs

Phase 2A

Avant Immunotherapeutics

1 program

Phase 2Emergent BioSolutions logo

Emergent BioSolutions

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Sanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

19programs
Vaccine1158%
Small molecule842%

Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed9 · 75%
Unknown status2 · 17%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
Not yet recruiting·GSK logoGSK·Phase 2·NCT07286370·537 enrolled
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
Completed·AAvant Immunotherapeutics·Phase 2·NCT00498654·180 enrolled
Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00342628·301 enrolled
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
Completed·IInternational Vaccine Institute·Phase 4·NCT00125008·37,673 enrolled
Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever
Completed·—·Phase 2·NCT07150065·360 enrolled
Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children
Completed·ZZiauddin University·Phase 4·NCT04154722·126 enrolled
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
Completed·HHelsinki University Central Hospital·Phase 4·NCT06104345·65 enrolled
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Completed·Emergent BioSolutions logoEmergent BioSolutions·Phase 2·NCT00679172·187 enrolled
This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever
Completed·SSheikh Zayed Medical College·Phase 4·NCT07445282·90 enrolled
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
Completed·GSK logoGSK·Phase 1/2·NCT05480800·155 enrolled
Typhoid Fever: Combined vs. Single Antibiotic Therapy
Unknown status·SSheba Medical Center·Phase 4·NCT02224040·120 enrolled
Cellular Immune Responses in Typhoid Fever Patients and Vaccinees
Unknown status·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 1·NCT03600025·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)